InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,399.45
(
-0.77%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

vidpok45

Send PM Follow Ignore
Followers 0
Posts 4859
Boards Moderated 0
Alias Born 06/15/2010

vidpok45

Re: None

Wednesday, 10/26/2016 9:13:06 AM

Wednesday, October 26, 2016 9:13:06 AM

Post# of 80490
I always said Alectinib is inferior to Brigatinib. Additional proof today: "Alectinib patients can die after suffering the G1202r mutation but Brigatinib patients DO NOT SUFFER RELAPSE as Alectininb patients DO from this mutation. In addition, Alectinib patients are sick as dogs from that drug. Brigatinib patients tolerate the drug very well and enjoy a good quality of life. Therefore those here who compate Alectinib to Brigatinib are simply WRONG!
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up